NCT03386500View on ClinicalTrials.gov

Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 28, 2017

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2029

Conditions
Anal Cancer, Squamous Cell CarcinomaRadiation Exposure
Interventions
DRUG

BMX-001

BMX-001 at escalating doses in combination with standard RT, 33 fractions to 59.4 Gy, plus Mitomycin at the standard dosing of 10 mg/m2 administered IV bolus at day 1 and day 29 as well as 5FU 1g/m2/d day 1-4 and 29-32.

Trial Locations (1)

68198

University of Nebraska Medical Center, Omaha

Sponsors

Collaborators (1)

BioMimetix JV, LLC
All Listed Sponsors
collaborator

BioMimetix JV, LLC

INDUSTRY

lead

University of Nebraska

OTHER